Apimeds Pharmaceuticals Net Income From Continuing Ops Over Time
| APUS Stock | 1.71 0.07 3.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Apimeds Pharmaceuticals Performance and Apimeds Pharmaceuticals Correlation. Is there potential for Diversified Capital Markets market expansion? Will Apimeds introduce new products? Factors like these will boost the valuation of Apimeds Pharmaceuticals. If investors know Apimeds will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apimeds Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Apimeds Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Apimeds's balance sheet. Smart investors calculate Apimeds Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Apimeds Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Apimeds Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apimeds Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Apimeds Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Apimeds Pharmaceuticals and related stocks such as Talphera, MIRA Pharmaceuticals, and Scynexis Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TLPH | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (40.4 M) | (35.1 M) | 59.1 M | (10.3 M) | (13 M) | (15 M) | (15.7 M) |
| MIRA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (7.1 M) | (7.5 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| SCYX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (28.3 M) | (30 M) | (25.1 M) | (12.5 M) | (53.7 M) | (55.2 M) | (32.9 M) | (62.8 M) | 72.2 M | (21.3 M) | (24.5 M) | (25.7 M) |
| MLSS | (1.5 M) | (1.5 M) | (520.4 K) | 1.1 M | (1.7 M) | (3.1 M) | (6.5 M) | (5.2 M) | (8 M) | (7.7 M) | (7.4 M) | (6.9 M) | (8.8 M) | (7 M) | (4.7 M) | (4.2 M) | (4.5 M) |
| IGC | (7.9 M) | (7.9 M) | (2.3 M) | (3 M) | (4.7 M) | (2.8 M) | (1.9 M) | (1.8 M) | (4.1 M) | (7.3 M) | (8.8 M) | (15 M) | (11.5 M) | (13 M) | (7.1 M) | (6.4 M) | (6.7 M) |
| POCI | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (614.9 K) | (1.4 M) | (102.8 K) | (928.4 K) | (144.6 K) | (3 M) | (5.8 M) | (5.2 M) | (4.9 M) |
| QTTB | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
| ANTX | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (21.5 M) | (41 M) | (59.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (36.6 M) | (69.4 M) | (74.7 M) | (65.6 M) | (55.7 M) | (50.1 M) | (52.6 M) |
| MYO | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (3.7 M) | (3.6 M) | (12.1 M) | (10.3 M) | (10.7 M) | (11.6 M) | (10.4 M) | (10.7 M) | (7.9 M) | (6.2 M) | (5.6 M) | (5.8 M) |
Apimeds Pharmaceuticals and related stocks such as Talphera, MIRA Pharmaceuticals, and Scynexis Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Apimeds Pharmaceuticals US | APUS |
Specialization | Financials, Drug Manufacturers - Specialty & Generic |
| Business Address | B4-204A5, Business Centre |
| Exchange | NYSE MKT Exchange |
null 1.71
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.